دورية أكاديمية

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

التفاصيل البيبلوغرافية
العنوان: Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
المؤلفون: Yu, Shengyuan, Kim, Byung-Kun, Guo, Aihong, Kim, Man-Ho, Zhang, Mingjie, Wang, Zhen, Liu, Jianguang, Moon, Heui-Soo, Tan, Ge, Yang, Qian, McGrath, Donnie, Hanna, Michael, Stock, David A, Gao, Yanfei, Croop, Robert, Lu, Zhihong
المصدر: The Lancet Neurology ; volume 22, issue 6, page 476-484 ; ISSN 1474-4422
بيانات النشر: Elsevier BV
سنة النشر: 2023
المجموعة: ScienceDirect (Elsevier - Open Access Articles via Crossref)
مصطلحات موضوعية: Neurology (clinical)
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1016/s1474-4422(23)00126-6
الإتاحة: https://doi.org/10.1016/s1474-4422Test(23)00126-6
https://api.elsevier.com/content/article/PII:S1474442223001266?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1474442223001266?httpAccept=text/plainTest
حقوق: https://www.elsevier.com/tdm/userlicense/1.0Test/ ; https://doi.org/10.15223/policy-017Test ; https://doi.org/10.15223/policy-037Test ; https://doi.org/10.15223/policy-012Test ; https://doi.org/10.15223/policy-029Test ; https://doi.org/10.15223/policy-004Test
رقم الانضمام: edsbas.98E498EF
قاعدة البيانات: BASE